Journal of Medicinal Chemistry · 2000 · 39 citations · 12 references
MedicineMedicinal ChemistryPharmacologyMolecular PharmacologyOrganic ChemistryStructure-activity RelationshipsCardiovascular PharmacodynamicsCardiovascular PharmacologyPotency OptimizationStructure-activity Relationship AnalysisCardiovascular Drug PharmacologyMedicinal Chemistry ApplicationsPde5 InhibitorsPhosphodiesterase InhibitionPhosphodiesterase RegulationPhosphodiesterase SignalingPhosphodiesterase Type 5 InhibitorsPhosphodiesterase-4 Inhibitors
We synthesized various 4-(3-chloro-4-methoxybenzyl)aminophthalazines substituted at the 1- and 6-positions and evaluated their inhibitory activity toward phosphodiesterase 5 (PDE5) and their vasorelaxant activity in isolated porcine coronary arteries precontracted with prostaglandin F2alpha (10(-5) M). The preferred substituents at the 1-position of the phthalazine were 4-hydroxypiperidino, 4-hydroxymethylpiperidino, 4-(2-hydroxyethyl)piperidino, and 4-oxopiperidino. Among these compounds, [4-(3-chloro-4-methoxybenzyl)amino-1-(4-hydroxy)piperidino]-6-phthala zinecarbonitrile monohydrochloride (13) exhibited potent PDE5 inhibitory activity (IC(50) = 0.56 nM) with >1700-fold high selectivity over other PDE isozymes (PDE1-4). Compound 13 exhibited the most potent vasorelaxant action (EC(50) = 13 nM) in this series of compounds. Compound 13 reduced mean pulmonary arterial pressure by 29.9 +/- 3.1% when administered intravenously at 30 microg/kg to the chronically hypoxic rats and had an apparent oral bioavailability of about 19.5% in rats and was selected for further biological evaluation.
12
N.K. Terrett, Andrew Bell, David Brown et al. · Bioorganic & Medicinal Chemistry Letters · 1996 · 606 citations
Yasutaka Takase, T. Saeki, Hideyuki Adachi et al. · Journal of Medicinal Chemistry · 1994 · 102 citations · Full text